HIGHLIGHTS
- who: Endocrine-Related and collaborators from the University of Texas MD Anderson Center, Houston, Texas, USA have published the research work: Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma, in the Journal: (JOURNAL)
- what: The aim of this study is to present the complete biomarker response dataset from pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 metaiodobenzylguanidine in patients with advanced pheochromocytoma or paraganglioma. Previously, as the biochemical response was a secondary endpoint and not the focus of the pivotal clinical study, the authors only . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.